期刊文献+

miR-143通过靶向FASN抑制肝癌HepG2细胞脂质形成

Inhibition of the lipogenesis of hepatocellular carcinoma HepG2 cells by miR-143 via suppressing FASN
下载PDF
导出
摘要 目的研究miR-143对肝癌Hep G2细胞脂质形成的影响及其分子机制。方法应用qRT-PCR方法检测miR-143在临床肝癌和癌旁组织以及肝癌细胞系和正常肝细胞系中的表达。通过油红O染色实验检测miR-143对肝癌细胞脂质形成的影响。Western blotting检测miR-143对肝癌细胞中脂肪酸合成酶(FASN)表达的影响。通过报告基因实验检测miR-143及其抑制子对报告基因载体FASN-CDS活性的影响。结果 qRTPCR结果表明在临床肝癌组织和Hep G2细胞中miR-143的表达显著低于癌旁组织和Chang liver肝细胞系(P<0.01)。油红O染色实验结果显示,miR-143能显著降低肝癌细胞中脂质的形成。qRT-PCR和Western blotting结果证实,miR-143可以显著下降FASN的mRNA和蛋白表达水平。报告基因检测结果表明,在Hep G2细胞中miR-143可以显著降低FASN-CDS报告基因的活性(P<0.01);相反,miR-143抑制子可以显著升高FASN-CDS的活性(P<0.01)。在Hep G2细胞中miR-143抑制子可以上调FASN的表达并促进脂质形成。结论 miR-143可以通过抑制FASN的表达阻碍肝癌细胞脂质形成。 Objective To investigate the effects of miR-143 on the lipogenesis of hepatocellular carcinoma Hep G2 cells and the molecular mechanism. Methods Expressions of miR-143 of the clinical hepatocarcinoma tissue,para cancer tissue, hepatocellular carcinoma cell line, and normal liver cell line were detected by quantitative realtime polymerase chain reaction( qRT-PCR). The effect of miR-143 on the lipogenesis of hepatocellular carcinoma cells was detected by the oil red O staining assay. The effect of miR-143 on the expression of fatty acid synthase( FASN) of hepatocellular carcinoma cells was detected by the Western blotting. The effects of miR-143 and its inhibitor on the activity of reporter gene vector FASN-CDS were detected by the reporter gene assays. Results The results of qRT-PCR showed that the expression of miR-143 of the clinical hepatocarcinoma tissue and Hep G2 cells significantly lower than that of the para cancer tissue and Chang liver cell line( P〈0. 01). The results of oil red O staining assay indicated that miR-143 significantly decreased the lipid formation of hepatocellular carcinoma cells.The results of qRT-PCR and Western blotting showed that miR-143 significantly decreased mRNA and protein levels of FASN. The results of reporter gene assays indicated that miR-143 in Hep G2 cells significantly decreased the activity of FASN-CDS( P〈0. 01), while the inhibitor of miR-143 significantly increased the activity of FASN-CDS( P〈0. 01). The inhibitor of miR-143 in Hep G2 cells was able to up-regulate the expression of FASN and enhance the lipogenesis. Conclusion MiR-143 can inhibit the lipogenesis of hepatocellular carcinoma cells by suppressing the expression of FASN.
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2015年第3期337-342,共6页 Journal of Shanghai Jiao tong University:Medical Science
基金 中国肝炎防治基金(TQGB20120013)~~
关键词 MIR-143 肝癌 脂质形成 FASN miR-143 hepatoma lipogenesis FASN
  • 相关文献

参考文献24

  • 1Zaidi N, Lupien L, Kuemmerle NB, et al. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids[ J]. Prog Lipid Res, 2013, 52(4) : 585 -589.
  • 2Flavin R, Peluso S, Nguyen PL, et al. Fatty acid synthase as a potential therapeutic target in cancer[ J J. Future Oncol, 2010, 6 (4) : 551 -562.
  • 3Gonzalez-Gaerrico AM, Lupu R. Fatty acid synthase (FASN) as a therapeutic target for breast cancer metastasis [ J ]. Cancer Res, 2009, 69(24): 876s.
  • 4Fsuji T, Yoshinaga M, Togami S, et al. Fatty acid synthase expres- sion and clinicopathologieal findings in endometrial cancer[J]. Acta 9bstet Gyn Scan, 2004, 83(6) : 586 -590.
  • 5Piyathilake C J, Frost AR, Manne U, et al. Elevated expression of fatty acid synthase ( FASE ) in squamous cell cancer of the lung[ J]. FASEB J, 2000, 14(4) : A789.
  • 6Wang Y, Kuhajda FP, Li JN, et al. Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients[J]. Cancer Lett, 2001, 167( 1 ) : 99 - 104.
  • 7Barrel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281 -297.
  • 8Calin GA, Croce CM. MicroRNA signatures in human cancers[ J]. Nat Rev Cancer, 2006, 6(11) : 857 -866.
  • 9Zhang Y, Yang P, Wang XF. Microenvironmental regulation of cancer metastasis by miRNAs [J]. Trends Cell Biol, 2014, 24 (3) : 153 - 160.
  • 10Koutsouki E. miRNAs responsible for inhibiting angiogenesis in cancer[ J ]. Nanomedicine (Lond) 2013, 8 ( 11 ) : 1740 - 1741.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部